La colelitiasi in età pediatrica. Il punto di vista del clinico - SIGENP
La colelitiasi in età pediatrica. Il punto di vista del clinico - SIGENP
La colelitiasi in età pediatrica. Il punto di vista del clinico - SIGENP
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Key Po<strong>in</strong>ts<br />
6<br />
• Gli eos<strong>in</strong>ofili sono le cellule granulocitiche<br />
<strong>in</strong>fiammatorie che si ritrovano<br />
con più frequenza nei tessuti<br />
<strong>di</strong> pazienti con malattie gastro<strong>in</strong>test<strong>in</strong>ali<br />
eos<strong>in</strong>ofile e possono svolgere<br />
funzioni <strong>di</strong>st<strong>in</strong>te a seconda <strong>del</strong><br />
microambiente <strong>in</strong> cui si trovano<br />
(protezione/danno nei confronti<br />
<strong>del</strong>l’ospite)<br />
• <strong>Il</strong> loro ruolo nelle malattie <strong>in</strong>test<strong>in</strong>ali<br />
non può essere al momento considerato<br />
certo: fondamentale per<br />
la ricerca <strong>in</strong> corso e per la cura<br />
cl<strong>in</strong>ica sarà l’analisi non solo <strong>del</strong><br />
numero degli eos<strong>in</strong>ofili presenti nei<br />
tessuti, ma anche dei mo<strong>del</strong>li <strong>di</strong><br />
eos<strong>in</strong>ofilia, <strong>del</strong>la localizzazione e<br />
<strong>del</strong>le caratteristiche <strong>in</strong>fiammatorie<br />
associate<br />
• Non sono attualmente note misure<br />
preventive per le malattie <strong>in</strong>test<strong>in</strong>ali<br />
associate a eos<strong>in</strong>ofilia, se<br />
non per l’esofagite eos<strong>in</strong>ofila<br />
• L’anti-IL-5 è un farmaco biologico<br />
che sembra promettente nelle<br />
malattie gastro<strong>in</strong>test<strong>in</strong>ali eos<strong>in</strong>ofile<br />
Topic High Light<br />
ESPGHAN - NASPGHAN<br />
ridurre l’eos<strong>in</strong>ofilia esofagea. Sfide per il futuro sono rappresentate dalla determ<strong>in</strong>azione<br />
<strong>del</strong>l’impatto <strong>del</strong>la malattia e dei trattamenti sulla qualità <strong>del</strong>la vita, l'identificazione<br />
degli end-po<strong>in</strong>t terapeutici e la scoperta <strong>di</strong> nuovi bersagli terapeutici.<br />
BIBLIOGRAFIA<br />
1. Masterson JC, Furuta GT, Lee JJ. Update on cl<strong>in</strong>ical and immunological features of<br />
eos<strong>in</strong>ophilic gastro<strong>in</strong>test<strong>in</strong>al <strong>di</strong>seases. Current op<strong>in</strong>ion <strong>in</strong> gastroenterology 2011;27:515-22.<br />
2. Woodruff SA, Masterson JC, Fillon S, Rob<strong>in</strong>son ZD, Furuta GT. Role of eos<strong>in</strong>ophils <strong>in</strong><br />
<strong>in</strong>flammatory bowel and gastro<strong>in</strong>test<strong>in</strong>al <strong>di</strong>seases. Journal of pe<strong>di</strong>atric gastroenterology and<br />
nutrition 2011;52:650-61.<br />
3. Blanchard C, Rothenberg ME. Biology of the eos<strong>in</strong>ophil. Adv Immunol 2009;101:81-121.<br />
4. Yousefi S, Gold JA, And<strong>in</strong>a N, Lee JJ, Kelly AM, Kozlowski E, Schmid I, Straumann A,<br />
Reichenbach J, Gleich GJ, Simon HU. Catapult-like release of mitochondrial DNA by<br />
eos<strong>in</strong>ophils contributes to antibacterial defense. Nat Med 2008;14:949-53.<br />
5. Coll<strong>in</strong>s MH. Histopathology associated with eos<strong>in</strong>ophilic gastro<strong>in</strong>test<strong>in</strong>al <strong>di</strong>seases. Immunol<br />
Allergy Cl<strong>in</strong> North Am 2009;29:109-17, x-xi.<br />
6. Odze RD. Pathology of eos<strong>in</strong>ophilic esophagitis: what the cl<strong>in</strong>ician needs to know.<br />
Am J Gastroenterol 2009;104:485-90.<br />
7. Kagalwalla AF, Akhtar N, Woodruff SA, Rea BA, Masterson JC, Mukkada V, Parashette KR,<br />
Du J, Fillon S, Protheroe CA, Lee JJ, Amsden K, Mel<strong>in</strong>-Aldana H, Capocelli KE, Furuta GT,<br />
Ackerman SJ. Eos<strong>in</strong>ophilic esophagitis: Epithelial mesenchymal transition contributes to<br />
esophageal remo<strong>del</strong><strong>in</strong>g and reverses with treatment. The Journal of Allergy and Cl<strong>in</strong>ical<br />
Immunology 2012.<br />
8. Furuta GT, Liacouras CA, Coll<strong>in</strong>s MH, Gupta SK, Just<strong>in</strong>ich C, Putnam PE, Bonis P, Hassall<br />
E, Straumann A, Rothenberg ME. Eos<strong>in</strong>ophilic esophagitis <strong>in</strong> children and adults: a systematic<br />
review and consensus recommendations for <strong>di</strong>agnosis and treatment. Gastroenterology<br />
2007;133:1342-63.<br />
9. Liacouras CA, Furuta GT, Hirano I, Atk<strong>in</strong>s D, Attwood SE, Bonis PA, Burks AW, Chehade M,<br />
Coll<strong>in</strong>s MH, Dellon ES, Dohil R, Falk GW, Gonsalves N, Gupta SK,<br />
10. Assa'ad AH, Gupta SK, Coll<strong>in</strong>s MH, Thomson M, Heath AT, Smith DA, Perschy TL,<br />
Jurgensen CH, Ortega HG, Aceves SS. An antibody aga<strong>in</strong>st IL-5 reduces numbers of<br />
esophageal <strong>in</strong>traepithelial eos<strong>in</strong>ophils <strong>in</strong> children with eos<strong>in</strong>ophilic esophagitis.<br />
Gastroenterology 2011;141:1593-604.<br />
11. Spergel JM, Rothenberg ME, Coll<strong>in</strong>s MH, Furuta GT, Markowitz JE, Fuchs G, 3rd,<br />
O'Gorman MA, Abonia JP, Young J, Henkel T, Wilk<strong>in</strong>s HJ, Liacouras CA. Reslizumab <strong>in</strong><br />
children and adolescents with eos<strong>in</strong>ophilic esophagitis: results of a double-bl<strong>in</strong>d, randomized,<br />
placebo-controlled trial. The Journal of Allergy and Cl<strong>in</strong>ical Immunology 2012;129:456-63,<br />
463 e1-3.